文献速递物质与行为成瘾

新冠疫情期间医保受益人远程医疗使用、阿片类使用障碍药物获取与保留及医疗治疗过量

Receipt of Telehealth Services, Receipt and Retention of Medications for Opioid Use Disorder, and Medically Treated Overdose Among Medicare Beneficiaries Before and During the COVID-19 Pandemic.
PubMed 文献 · JAMA Psychiatry · 2022-01-01

这项探索性纵向队列研究基于美国联邦医疗保险(Medicare)2018年9月至2021年2月数据,比较疫情前后阿片类使用障碍(OUD)受益人远程医疗使用、OUD药物(MOUD)获取与保留及医疗治疗过量情况。疫情期间OUD相关远程医疗和行为健康远程医疗使用率及MOUD获取率均显著升高,医疗治疗过量比例相似;疫情期间接受OUD相关远程医疗与更高的MOUD保留几率和更低的医疗治疗过量几率相关。

要点

  • 疫情期间OUD相关远程医疗使用率19.6%远高于疫情前0.6%,行为健康远程医疗41.0% vs 1.9%。
  • 疫情期间MOUD获取率12.6%高于疫情前10.8%,医疗治疗过量比例相似(18.4% vs 18.5%)。
  • 疫情期间接受OUD相关远程医疗与更高MOUD保留(aOR 1.27)和更低过量(aOR 0.67)相关。

核心结论

  • 疫情期间扩大远程医疗和MOUD供应灵活性的紧急授权被Medicare受益人用于启动OUD相关照护,并与改善治疗保留和降低医疗治疗过量几率相关。

主要发现

  • 疫情期间队列相比疫情前队列,接受OUD相关远程医疗服务比例为19.6% vs 0.6%(P<.001),行为健康相关远程医疗服务为41.0% vs 1.9%(P<.001),MOUD获取率为12.6% vs 10.8%(P<.001)。
  • 疫情期间队列中,接受OUD相关远程医疗服务与更高的MOUD保留几率相关(aOR 1.27;95%CI 1.14-1.41),与更低的医疗治疗过量几率相关(aOR 0.67;95%CI 0.63-0.71)。
  • 疫情期间队列中,仅从阿片类药物治疗项目获得MOUD者(aOR 0.54;95%CI 0.47-0.63)和仅从药房获得丁丙诺啡者(aOR 0.91;95%CI 0.84-0.98)相比未接受MOUD者,医疗治疗过量几率更低。

临床怎么用

  • 在OUD照护中可考虑利用远程医疗提供OUD相关和行为健康服务,以改善MOUD治疗保留并降低医疗治疗过量风险。
  • 应优先扩大MOUD供应并提高治疗保留,尤其关注从阿片类药物治疗项目获取美沙酮或从药房获取丁丙诺啡的路径。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Federal emergency authorities were invoked during the COVID-19 pandemic to expand use of telehealth for new and continued care, including provision of medications for opioid use disorder (MOUD). OBJECTIVE: To examine receipt of telehealth services, MOUD (methadone, buprenorphine, and extended-release [ER] naltrexone) receipt and retention, and medically treated overdose before and during the COVID-19 pandemic. DESIGN, SETTING, AND PARTICIPANTS: This exploratory longitudinal cohort study used data from the US Centers for Medicare & Medicaid Services from September 2018 to February 2021. Two cohorts (before COVID-19 pandemic from September 2018 to February 2020 and during COVID-19 pandemic from September 2019 to February 2021) of Medicare fee-for-service beneficiaries 18 years and older with an International Statistical Classification of Diseases, Tenth Revision, Clinical Modification OUD diagnosis. EXPOSURES: Pre-COVID-19 pandemic vs COVID-19 pandemic cohort demographic characteristics, medical and substance use, and psychiatric comorbidities. MAIN OUTCOMES AND MEASURES: Receipt and retention of MOUD, receipt of OUD and behavioral health-related telehealth services, and experiencing medically treated overdose. RESULTS: The pre-COVID-19 pandemic cohort comprised 105 240 beneficiaries; of these, 61 152 (58.1%) were female, 71 152 (67.6%) were aged 45 to 74 years, and 82 822 (79.5%) non-Hispanic White. The COVID-19 pandemic cohort comprised 70 538 beneficiaries; of these, 40 257 (57.1%) were female, 46 793 (66.3%) were aged 45 to 74 years, and 55 510 (79.7%) were non-Hispanic White. During the study period, a larger percentage of beneficiaries in the pandemic cohort compared with the prepandemic cohort received OUD-related telehealth services (13 829 [19.6%] vs 593 [0.6%]; P < .001), behavioral health-related telehealth services (28 902 [41.0%] vs 1967 [1.9%]; P < .001), and MOUD (8854 [12.6%] vs 11 360 [10.8%]; P < .001). The percentage experiencing a medically treated overdose during the study period was similar (18.5% [19 491 of 105 240] in the prepandemic cohort vs 18.4% [13 004 of 70 538] in the pandemic cohort; P = .65). Receipt of OUD-related telehealth services in the pandemic cohort was associated with increased odds of MOUD retention (adjusted odds ratio [aOR], 1.27; 95% CI, 1.14-1.41) and lower odds of medically treated overdose (aOR, 0.67; 95% CI, 0.63-0.71). Among beneficiaries in the pandemic cohort, those receiving MOUD from opioid treatment programs only (aOR, 0.54; 95% CI, 0.47-0.63) and those receiving buprenorphine from pharmacies only (aOR, 0.91; 95% CI, 0.84-0.98) had lower odds of medically treated overdose compared with beneficiaries who did not receive MOUD. CONCLUSIONS AND RELEVANCE: Emergency authorities to expand use of telehealth and provide flexibilities for MOUD provision during the pandemic were used by Medicare beneficiaries initiating an episode of OUD-related care and were associated with improved retention in care and reduced odds of medically treated overdose. Strategies to expand provision of MOUD and increase retention in care are urgently needed.

来源:JAMA Psychiatry,查看原文。版权归原作者所有。

引用

  1. Jones CM, Shoff C, Hodges K, et al. Receipt of Telehealth Services, Receipt and Retention of Medications for Opioid Use Disorder, and Medically Treated Overdose Among Medicare Beneficiaries Before and During the COVID-19 Pandemic. JAMA Psychiatry. 2022. PMID: 36044198. doi:10.1001/jamapsychiatry.2022.2284

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。